Blocked Pipeline Leads Teva’s US Generics To Fall Well Below $1bn Floor
As FX Headwinds Chip Hundreds Of Millions More From Top-Line Guidance
Teva’s final quarterly earnings call of the year was indicative of its continued need to push valuable pipeline projects in the US to commercialization, as it once again lowered its full-year 2022 revenue guidance.
